Welcome to our dedicated page for Intercure news (Ticker: INCR), a resource for investors and traders seeking the latest updates and insights on Intercure stock.
InterCure Ltd. reports developments for a medical cannabis company operating as Canndoc, with activities in research, cultivation, production and distribution of pharmaceutical-grade cannabis products. Company updates commonly cover financial results, Adjusted EBITDA, operating cash flow, recovery of production and sales after damage to its southern facility, and the role of Canndoc as a licensed Israeli cannabis producer with GMP-certified products.
News also includes international market activity and partnerships, including German market revenue and brand collaborations, as well as cannabis regulatory developments in the United States and Europe. Corporate items include Nasdaq minimum bid compliance, ordinary-share capital actions, annual meeting matters, material agreements and board leadership changes.
InterCure (Nasdaq: INCR) reached a final settlement with the Israeli Tax Authorities and Compensation Fund for indirect damages from the October 7, 2023 attacks, securing total compensation of NIS 230 million (~US$77 million). The company had originally claimed over NIS 300 million and previously received NIS 101 million in advance payments.
InterCure plans to use its strengthened financial position to accelerate rehabilitation of Canndoc’s severely damaged Nir Oz cultivation and production facility, aiming to restore full operations. According to the company, rebuilding Nir Oz is central to restoring production capacity and supporting expansion, particularly in the growing German medical cannabis market.
InterCure (Nasdaq: INCR) plans a 1-for-5 reverse share split of its ordinary shares, effective at market open on August 24, 2026, when trading will begin on a split-adjusted basis under the same ticker. The new CUSIP will be M549GJ368.
The move aims to raise InterCure’s share price to regain compliance with Nasdaq’s $1.00 minimum bid requirement and support continued listing. Shareholders approved the action on August 11, 2026. Authorized share capital will adjust from 100,000,000 to 20,000,000 ordinary shares, and issued and outstanding shares from 59,228,556 to about 11,845,711, with fractional shares rounded down.
InterCure (Nasdaq: INCR) entered a binding term sheet for a NIS 22 million private placement, potentially rising to NIS 54 million with warrant exercises. The deal, led by CEO Alexander Rabinovich and pharma-focused hedge funds, aims to fund facility recovery and global medical cannabis expansion.
InterCure (Nasdaq: INCR) completed the first tranche (50%) of its Botanico acquisition, gaining exclusive access to U.S. cannabis genetics, premium brands, AI-driven technologies and alliances with operators such as The Flowery.
InterCure is issuing 2,471,061 shares at initial closing and may issue 2,470,073 more. The company reports first meaningful revenues from Germany, has built a local team, plans multiple H2 product launches, and is reviewing opportunities in regulated U.S. medical cannabis markets following federal rescheduling.
InterCure (NASDAQ: INCR) reported FY2025 results: revenue of NIS 270.2 million, net loss of NIS 36.8 million, Adjusted EBITDA of NIS 46.6 million and positive operating cash flow of NIS 17 million. The company resumed production at Nir Oz, launched 75+ GMP SKUs, completed strategic deals including the Botanico purchase and a Cannasoul investment, received NIS 82 million in compensation advances, and held NIS 49 million cash at year-end.
The release notes continued recovery from the October 7, 2023 events and expanding revenues in Germany, with Botanico expected to contribute >NIS 30 million in H2 2026.
InterCure (Nasdaq: INCR) received a Nasdaq notice on February 25, 2026 for failing to meet the $1.00 minimum bid under Nasdaq Listing Rule 5450(a)(2).
The company has a 180-calendar day compliance period until August 24, 2026 to regain compliance by achieving a $1.00 closing bid for at least 10 consecutive business days. InterCure may seek an additional 180-day period by submitting a transfer application and intends to consider a reverse share split as part of its compliance plan.
InterCure (Nasdaq: INCR) reported preliminary 2025 results with estimated NIS 265 million revenue, roughly +11% vs. 2024, and positive Adjusted EBITDA for both halves (twelfth consecutive positive half). The company ended 2025 with NIS 43 million cash and nearly 20% H2 revenue growth, plus first significant German revenues.
Key actions include resumed Nir Oz production, >70 new GMP SKUs, an agreed acquisition of Botanico, a 28% Cannasoul stake, and NIS 81 million in compensation advances (NIS 251 million claim submitted).
InterCure (Nasdaq: INCR) entered a definitive Share Purchase Agreement and Collaboration Agreement with Cannasoul on Nov 3, 2025, taking a 28% ownership stake on a fully diluted basis and an exclusive path to 51% within two years.
The Collaboration Agreement formalizes joint research, development, and commercialization of evidence-based cannabis therapeutics and anticipates Prof. Dedi Meiri joining as Chair of an InterCure Scientific Advisory Board to accelerate R&D integration.
The transaction is subject to customary closing conditions and regulatory approvals; the release notes potential U.S. market opportunities tied to reported federal rescheduling discussions.
InterCure (NASDAQ: INCR) reported first half 2025 results: NIS 130 million revenue, NIS 12.6 million Adjusted EBITDA (10% margin) and NIS 12 million positive operating cash flow. Revenue rose 15% versus H2 2024 and 3% year‑over‑year. Net loss was NIS 1.8 million. Cash on hand improved to NIS 54 million from NIS 21 million a year earlier. The company resumed production at its Nir Oz facility, launched 40+ SKUs, received NIS 81 million in compensation advances against submitted damages of NIS 251 million, and signed a share purchase agreement to acquire ISHI to expand U.S. genetics and supply.
InterCure (NASDAQ: INCR) has announced the strategic acquisition of Botanico Ltd. (ISHI), a premium cannabis technology and brand company. The transaction will be executed in two phases, with InterCure acquiring 100% of ISHI for 4,924,261 ordinary shares, representing approximately 10% of InterCure's fully diluted shares.
The acquisition provides InterCure immediate access to advanced cultivation technologies, exclusive partnerships with leading U.S. cannabis operators including The Flowery, and premium American genetics. The deal comes amid potential cannabis rescheduling from Schedule I to Schedule III by the Trump administration, positioning InterCure to capitalize on evolving U.S. market opportunities.
The transaction is expected to close in Q1 2026, subject to regulatory approvals. ISHI's leadership team, including CEO Omer Layani and COO Dor Hershkovitz, will join InterCure's management. The acquisition is projected to be accretive within the first year.